Synergic Effects of Levamlodipine and Bisoprolol on Blood Pressure Reduction and Organ Protection in Spontaneously Hypertensive Rats

CNS Neuroscience and Therapeutics

Volumn 18, Issue 6, 2012, Pages 471-474

  Yang, Yan Ling ^a   Yu, Li Ting ^a   Wu, Zhao Tang ^a   Yu, Jian Guang ^a   Zhang, Jing Ming ^a   Chen, Qing Hua ^a   Bao, Yong Chu ^a   Tao, Xia ^c   Liu, Jian Guo ^b  

^a National Pharmaceutical Engineering and Research Center   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bisoprolol; Combination therapy; Hypertension; Levamlodipine; Stroke

Indexed keywords

AMLODIPINE BESYLATE; BISOPROLOL FUMARATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; AORTA DISEASE; AORTIC HYPERTROPHY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; BRADYCARDIA; CONTROLLED STUDY; DRUG POTENTIATION; ESSENTIAL HYPERTENSION; HEART VENTRICLE HYPERTROPHY; KIDNEY ATROPHY; KIDNEY DISEASE; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; SPONTANEOUSLY HYPERTENSIVE RAT; TACHYCARDIA;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BISOPROLOL; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MALE; NIACIN; PROBABILITY; RATS; RATS, INBRED SHR; TIME FACTORS;

EID: 84861880296     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2012.00323.x     Document Type: Article

References (25)

1. Endres M, Heuschmann PU, Laufs U, Hakim AM. Primary prevention of stroke: Blood pressure, lipids, and heart failure. Eur Heart J 2011;32:545-552.
2. Grassi G, Cifkova R, Laurent S, et al. Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: Results of the BP-CARE study. Eur Heart J 2011;32:218-225.
3. Yu JG, Zhou RR, Cai GJ. From hypertension to stroke: Mechanisms and potential prevention strategies. CNS Neurosci Ther 2011;17:577-584.
4. Redon J, Olsen MH, Cooper RS, et al. Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: Implications for control of high blood pressure. Eur Heart J 2011;32:1424-1431.
5. Hao CN, Huang ZH, Shi YQ, Lu W, Duan JL. A new index to predict the incidence of cerebral infarction. CNS Neurosci Ther 2011;17:783-784.
6. Bangalore S, Messerli FH, Wun CC, et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 2010;31:2897-2908.
7. Gorelick PB. New horizons for stroke prevention: PROGRESS and HOPE. Lancet Neurol 2002;1:149-156.
8. Franco V, Oparil S, Carretero OA. Hypertensive therapy: Part II. Circulation 2004;109:3081-3088.
9. Sever PS, Messerli FH. Hypertension management 2011: Optimal combination therapy. Eur Heart J 2011;32:2499-2506.
10. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high-blood pressure: The JNC 7 (Express) Report. JAMA 2003;289:2560-2572.
11. Cruickshank JM. New guidelines on hypertension. Lancet 2006;368:641.
12. Ling G, Liu AJ, Shen FM, Cai GJ, Liu JG, Su DF. Effects of combination therapy with atenolol and amlodipine on blood pressure control and stroke prevention in stroke-prone spontaneously hypertensive rats. Acta Pharmacol Sin 2007;28:1755-1760.
13. Han P, Shen FM, Xie HH, et al. The combination of atenolol and amlodipine is better than their monotherapy in preventing end organ damage in different types of hypertension in rats. J Cell Mol Med 2009;13:726-734.
14. Liu F, Qiu M, Zhai SD. Tolerability and effectiveness of (s)-amlodipine compared with racemic amlodipine in a systemic review and meta-analysis. Curr Ther Res Clin Exp 2010;71:1-29.
15. Miao CY, Xie HH, Zhan LS, Su DF. Blood pressure variability is more important than blood pressure level in determination of end-organ damage in rats. J Hypertens 2006;24:1125-1135.
16. Su DF. Treatment of hypertension based on measurement of blood pressure variability: Lessons from animal studies. Curr Opin Cardiol 2006;21:486-491.
17. Yang C, Zhang X, Song SW, Yu JG, Cai GJ. Cerebral artery remodeling in stroke- prone spontaneously hypertensive rats. CNS Neurosci Ther 2011;17:785-786.
18. Su DF, Xu LP, Miao CY, Xie HH, Shen FM, Jiang YY. Two useful methods for evaluating antihypertensive drugs in conscious freely moving rats. Acta Pharmacol Sin 2004;25:148-151.
19. Xu LP, Miao CY, Shen FM, Jiang YY, Su DF. Synergism of atenolol and amlodipine on lowering and stabilizing blood pressure in spontaneously hypertensive rats. Fundam Clin Pharmacol 2004;18:33-38.
20. Mackay J, Mensah G. The atlas of heart disease and stroke. Geneva, Switzerland : World Health Organization, 2004.
21. Franco V, Oparil S, Carretero OA. Hypertensive therapy: Part I. Circulation 2004;109:2953-2958.
22. Papadopoulos DP, Papademetriou V. Aggressive blood pressure control and stroke prevention: Role of calcium channel blockers. J Hypertens 2008;26:844-852.
23. Shikata C, Sekikawa T, Kimura N, et al. Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension. Exp Clin Cardiol 2007;12:33-36.
24. Xie HH, Miao CY, Jiang YY, Su DF. Synergism of atenolol and nitrendipine on hemodynamic amelioration and organ protection in hypertensive rats. J Hypertens 2005;23:193-201.
25. Liu Z, Zheng X, Yang X, Wang E, Wang J. Affinity and specificity of levamlodipine-human serum albumin interaction: Insights into its carrier function. Biophys J 2009;96:3917-3925.